Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-08-07 / Sci Rep 2018 Aug;8(1):11800Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-08-05 / BMJ Open 2018 08;8(8):e021701Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2018-07-30 / Oncoimmunology 2018;7(12):e1474318Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-07-30 / Clin. Exp. Med. 2018 Nov;18(4):535-546High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-07-27 / Cancer Immunol. Immunother. 2018 Oct;67(10):1545-1558Dendritic cell vaccines for high-grade gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-07-26 / Ther Clin Risk Manag 2018;14:1299-1313A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-1518Targeting dendritic cells in pancreatic ductal adenocarcinoma
/in Dendritic Cells, Exosome, International Publications, Pancreatic Cancer /von 2018-06-18 / Cancer Cell Int. 2018;18:85Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de